pri-med.com
Apr 28, 2025, 08:51
Andrew M. Evens: Brilliant Presentation on Long-Term Hodgkin Lymphoma Outcomes at BSH ASM
Andrew M. Evens, Deputy Director for Clinical Services at Rutgers Cancer Institute, shared the following insightful post on X:
“Brilliant presentation at British Society for Haematology ASM by Manchester Cancer Research Centre, NIHR Manchester Biomedical Research Centre Dr John Radford on long-term follow up for early-stage Hodgkin lymphoma patients treated on the RAPID trial. OS remains excellent in both groups (consolidative radiation and no RT) 15 years (92-94%).”
This post by Andrew M. Evens highlights promising long-term survival outcomes for early-stage Hodgkin lymphoma patients treated in the RAPID trial, whether they received consolidative radiation or not. He praised Dr. John Radford’s presentation at the British Society for Haematology Annual Scientific Meeting for showcasing these enduring results, reinforcing the strength of both treatment approaches after 15 years of follow-up.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 18, 2025, 13:40
May 18, 2025, 13:31
May 18, 2025, 12:54